These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 25342385

  • 1. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.
    J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
    [Abstract] [Full Text] [Related]

  • 2. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 3. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 4. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 5. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.
    Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L.
    J Nucl Med; 2021 Aug 01; 62(8):1075-1081. PubMed ID: 33277398
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep 01; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 8. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
    Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Clin Nucl Med; 2018 Apr 01; 43(4):225-231. PubMed ID: 29401151
    [Abstract] [Full Text] [Related]

  • 9. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan 01; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 10. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2014 Jul 01; 41(7):1280-92. PubMed ID: 24577951
    [Abstract] [Full Text] [Related]

  • 11. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y, Ando M, Watanabe H, Ono M.
    Ann Nucl Med; 2024 Oct 01; 38(10):847-851. PubMed ID: 38976087
    [Abstract] [Full Text] [Related]

  • 12. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.
    J Med Chem; 2013 Aug 08; 56(15):6108-21. PubMed ID: 23799782
    [Abstract] [Full Text] [Related]

  • 13. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
    Santos-Cuevas C, Davanzo J, Ferro-Flores G, García-Pérez FO, Ocampo-García B, Ignacio-Alvarez E, Gómez-Argumosa E, Pedraza-López M.
    Nucl Med Biol; 2017 Sep 08; 52():1-6. PubMed ID: 28575794
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
    Schmidkonz C, Atzinger A, Goetz TI, Beck M, Ritt P, Prante O, Kuwert T, Bäuerle T, Cordes M.
    Clin Nucl Med; 2020 Feb 08; 45(2):105-112. PubMed ID: 31876822
    [Abstract] [Full Text] [Related]

  • 15. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 08; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 16. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saji H.
    Bioorg Med Chem; 2016 May 15; 24(10):2251-6. PubMed ID: 27073053
    [Abstract] [Full Text] [Related]

  • 17. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 15; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 18. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 15; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and Evaluation of 99mTc-Labeled DPro-Gly-Containing Tracers Targeting PSMA.
    Li Z, Jiang Y, Ruan Q, Yin G, Han P, Duan X, Zhang J.
    Mol Pharm; 2024 Oct 07; 21(10):5305-5314. PubMed ID: 39298677
    [Abstract] [Full Text] [Related]

  • 20. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.
    J Nucl Med; 2016 Oct 07; 57(Suppl 3):79S-89S. PubMed ID: 27694178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.